BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 36216409)

  • 1. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
    Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
    Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M
    Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose.
    Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L
    Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.
    Shirata M; Ito I; Tanaka M; Murata K; Murakami K; Ikeda H; Oi I; Hamao N; Nishioka K; Hayashi Y; Nagao M; Hashimoto M; Ito H; Ueno H; Morinobu A; Hirai T
    Clin Exp Med; 2023 Dec; 23(8):4707-4720. PubMed ID: 37582911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
    Picchianti-Diamanti A; Aiello A; Laganà B; Agrati C; Castilletti C; Meschi S; Farroni C; Lapa D; Najafi Fard S; Cuzzi G; Cimini E; Grassi G; Vanini V; Di Rosa R; Salemi S; Nalli G; Salmi A; Repele F; Altera AMG; Maffongelli G; Palazzolo C; Vita S; Leone S; Puro V; Capobianchi MR; Ippolito G; Nicastri E; Goletti D
    Front Immunol; 2021; 12():740249. PubMed ID: 34594343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
    Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
    Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
    Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
    Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
    Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Bystrup A; Byg KE; Johansen IS; Mittl K; Rowles W; Mcpolin K; Spencer C; Sagan S; Gerungan C; Wilson MR; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
    Mult Scler Relat Disord; 2021 Nov; 56():103251. PubMed ID: 34571415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
    Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; de la Concepción MLR; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
    J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
    Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
    Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis.
    Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Kittanamongkolchai W
    Lupus Sci Med; 2022 Jul; 9(1):. PubMed ID: 35902168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
    Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
    Front Immunol; 2022; 13():960001. PubMed ID: 36311767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.